COVID-19: TCTMD’s Daily Dispatch for November 23
Regeneron’s antibody cocktail gets an EUA, more positive vaccine data, resilient seniors, the frequency of delirium, and more.
Regeneron’s antibody cocktail gets an EUA, more positive vaccine data, resilient seniors, the frequency of delirium, and more.
Whether that delay versus transfemoral access has an impact on patient outcomes remains a key question.
The findings suggest these types of patients continue to improve beyond 3-6 months and thus might benefit from longer rehab.
Although ORBITA-AF shows it can be done, and other trials are underway, not everyone is convinced it’s worth the effort.
It’s possible that other classes of antithrombotics may be worth adding to improve reperfusion, but that’s conjecture right now.
”Zero-degree positioning” may be one of the most important first steps in managing large vessel occlusions, study shows.
The findings shouldn’t, however, discourage those who want children from pursuing ART, experts say.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
Initial safety and efficacy findings from this first-in-human series “look really impressive,” but experts await further studies.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
As demand for the drug continues to rise, alternatives like the oral formulation and other injectable GLP-1s come into play.